

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2007 (20.09.2007)

PCT

(10) International Publication Number
WO 2007/105050 A1

(51) International Patent Classification:

C07D 257/06 (2006.01) **A61K 31/165** (2006.01)
C07C 233/18 (2006.01) **A61P 3/06** (2006.01)
C07C 271/16 (2006.01) **A61P 9/10** (2006.01)
C07C 275/24 (2006.01) **A61K 31/27** (2006.01)
A61K 31/41 (2006.01)

06340 (US). **ZENG, Dongxiang** [CN/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; c/o LAWRENCE, Jackie, Pfizer Inc. Ms8260-1615, Eastern Point Road, Groton, CT 06340 (US).

(21) International Application Number:

PCT/IB2007/000527

(22) International Filing Date:

26 February 2007 (26.02.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/780,993 10 March 2006 (10.03.2006) US
11/619,277 3 January 2007 (03.01.2007) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHANG, George** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **GARIGIPATI, Ravi Shanker** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **LEFKER, Bruce Allen** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **PERRY, David Austen** [GB/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIBENZYL AMINE COMPOUNDS AND DERIVATIVES

(57) Abstract: Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

WO 2007/105050 A1